TECHNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30
BIO-TECHNE Corp
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 24, 2026
$72.49−0.08 (-0.11%)
Close on Oct 19, 2026
- Market cap
- $11.40B
- P/E (TTM)
- 62.5
- Dividend yield
- 0.44%
BIO-TECHNE Corp revenue by segment
By business segment
| Revenue | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Protein Sciences | $874.62M | $869.90M | $871.43M | $867.90M | $870.25M | $857.76M | $844.66M | $830.78M | $830.90M | $839.92M | $844.24M | $850.45M | 72.0% | +0.5% |
| Diagnostics and Spatial Biology | $336.37M | $335.93M | $339.57M | $342.53M | $346.26M | $347.24M | $345.52M | $336.79M | $326.39M | – | – | – | 27.7% | -2.9% |
| Diagnostics and Genomics | – | – | – | – | – | – | – | – | $326.39M | $314.74M | $302.90M | $295.49M | – | – |
| Other Revenues from Business Held for Sale | – | – | – | – | – | $6.21M | $8.31M | – | $4.15M | – | – | – | – | – |
| Operating income | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Protein Sciences | $359.40M | $361.12M | $365.03M | $367.52M | $370.35M | $363.56M | $354.48M | $346.95M | $354.78M | $362.43M | $366.35M | $376.10M | -3.0% |
| Diagnostics and Spatial Biology | $37.70M | $33.01M | $31.12M | $25.93M | $21.32M | $27.30M | $26.98M | $28.29M | $24.55M | – | – | – | +76.8% |
| Diagnostics and Genomics | – | – | – | – | – | – | – | – | $24.55M | $27.83M | $31.19M | $34.93M | – |
By product or service
| Revenue | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product and Services | $1.19B | $1.19B | $1.19B | $1.19B | $1.20B | $1.19B | $1.17B | $1.15B | $1.14B | $1.13B | $1.12B | $1.12B | 97.9% | -0.5% |
| Consumables | $985.12M | $977.32M | $977.77M | $973.04M | $972.29M | $965.12M | $954.07M | $934.48M | $928.18M | $925.72M | $919.65M | $925.85M | 81.1% | +1.3% |
| Instruments | $110.63M | $108.00M | $106.44M | $107.71M | $112.09M | $110.28M | $110.66M | $109.62M | $108.27M | $109.06M | $108.01M | $110.49M | 9.1% | -1.3% |
| Services | $94.30M | $100.86M | $106.66M | $111.70M | $111.57M | $110.13M | $108.39M | $105.17M | $99.27M | $96.26M | $94.07M | $85.79M | 7.8% | -15.5% |
| Royalty revenues | $24.99M | $24.63M | $24.70M | $24.29M | $23.69M | $23.24M | $22.90M | $22.32M | $23.35M | $23.25M | $23.27M | $21.85M | 2.1% | +5.5% |
By region
| Revenue | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $635.37M | $645.66M | $660.11M | $673.46M | $683.23M | $684.38M | $675.77M | $663.66M | $657.75M | $655.05M | $644.93M | $646.14M | 52.3% | -7.0% |
| EMEA, excluding United Kingdom | $294.22M | $284.28M | $277.33M | $272.37M | $266.31M | $259.52M | $253.55M | $245.70M | $241.43M | $237.85M | $237.02M | $229.01M | 24.2% | +10.5% |
| China | $104.06M | $104.06M | $102.53M | $100.93M | $100.46M | $97.48M | $98.60M | $98.30M | $99.47M | $101.31M | $101.97M | $107.83M | 8.6% | +3.6% |
| APAC, excluding Greater China | $85.82M | $82.60M | $82.02M | $78.29M | $77.26M | $77.64M | $74.64M | $74.68M | $73.90M | $72.24M | $74.15M | $73.08M | 7.1% | +11.1% |
| United Kingdom | $56.28M | $56.61M | $54.57M | $54.09M | $54.83M | $51.80M | $54.07M | $51.50M | $50.01M | $51.32M | $50.01M | $50.20M | 4.6% | +2.7% |
| Rest of World | $39.29M | $37.61M | $39.02M | $37.60M | $37.55M | $37.95M | $39.38M | $37.74M | $36.50M | $36.51M | $36.93M | $37.72M | 3.2% | +4.6% |
From the segment and revenue-disaggregation notes of Bio-Techne's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.